Princess Kate's Health Problems Didn't Go When Treatment Stopped
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Princess Kate has described the "very scary, very daunting experience" of finishing her cancer treatment only to find she was still "not able to function normally at home."
The Princess of Wales made the remarks on Wednesday during a visit to the Royal Horticultural Society's Wellbeing Garden at Colchester Hospital in Essex, England, which aims to provide a space where staff, patients and visitors can enjoy being in nature.
"There is a whole phase when you finish your treatment, everybody expects you to be better—go. But that's not the case at all," she said.
Princess Kate during a visit to the RHS's Wellbeing Garden at Colchester Hospital on July 2, 2025, in Essex, U.K.
Princess Kate during a visit to the RHS's Wellbeing Garden at Colchester Hospital on July 2, 2025, in Essex, U.K.
Stefan Rousseau -Why It Matters
Kate announced she had finished chemotherapy in September and by January disclosed on social media that she was officially in remission.
However, her workload has continued to be lighter than it was before her health crisis and in June she appeared to cancel an announced visit to Ascot Racecourse. Newsweek understands the princess had not intended to go and the announcement she would be there was a result of a mix up between the palace and organizers.
Her latest comments lend greater insight, though, into why she is still maintaining a scaled-down workload six months after announcing she was in remission.
What To Know
Quoted by the Daily Mail, Kate told patients and volunteers: "You put on a sort of brave face, stoicism through treatment. Treatment's done, then it's like, 'I can crack on, get back to normal,' but actually the phase afterwards is really difficult.
"You're not necessarily under the clinical team any longer but you're not able to function normally at home as you perhaps once used to.
"And actually someone to help talk you through that, show you and guide you through that sort of phase that comes after treatment I think is really valuable."
Kate looked chic in a beige Blazé Milano blazer and matching striped Ralph Lauren shirt.
A palace press release said Wednesday's visit to Colchester Hospital was to "celebrate the incredible healing power of nature and raise awareness of the important role that spending time in nature plays in bringing us joy and supporting our mental, physical and spiritual wellbeing."
It was her first public appearance since it emerged that she was not attending Royal Ascot in June, underscoring her cautious approach to resuming royal duties.
The Princess' visit included planting "Catherine's Rose," a flower named in her honor, in the Wellbeing Garden. Proceeds from the rose's sales support a cancer charity, reflecting her ongoing commitment to cancer awareness and support.
Kate's openness about the challenges of posttreatment life offers a rare glimpse into the personal struggles faced by cancer survivors, highlighting the need for continued support and understanding beyond the completion of medical procedures.
What People Are Saying
The Kensington Palace press release said: "The Princess' visit coincides with the donation of 50 'Catherine's Rose' plants, named for The Princess by the RHS with funds from sales going to the Royal Marsden Cancer Charity, to Colchester Hospital.
"Five hundred 'Catherine's Rose' plants will be donated to wellbeing and community gardens across the UK this summer, including Maggie's gardens for people affected by cancer, East Anglia's Children's Hospices and Horatio's Gardens for those living with spinal injuries."
Jack Royston is chief royal correspondent for Newsweek, based in London. You can find him on Twitter at @jack_royston and read his stories on Newsweek's The Royals Facebook page.
Do you have a question about King Charles III, William and Kate, Meghan and Harry, or their family that you would like our experienced royal correspondents to answer? Email royals@newsweek.com. We'd love to hear from you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
22 minutes ago
- Newsweek
Freeze Dried Fruit Recall Sparks Warning to Customers Across the US
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Doehler Dry Ingredient Solutions, LLC is recalling the Member's Mark brand of freeze-dried fruit variety packs due to fears the product is contaminated with Listeria monocytogenes. Newsweek attempted to reach the company via phone on Friday for comment but could not leave a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. Listeria monocytogenes is a bacterium that poses significant health risks, particularly to pregnant women, newborns, older adults, and individuals with weakened immune systems, according to the FDA. What To Know In the alert, the FDA notes that the products were distributed from July 1, 2025, until July 25, 2025, at Sam's Club retail locations. The states and territories impacted by this recall are: Alabama Arizona California Colorado Connecticut Delaware Florida Georgia Hawaii Iowa Indiana Illinois Idaho Kansas Louisiana Maryland Maine Mississippi Minnesota Missouri Michigan Montana North Carolina North Dakota Nebraska New Hampshire New Jersey New Mexico Nevada New York Ohio Oklahoma Pennsylvania South Carolina South Dakota Tennessee Texas Utah Virginia Wisconsin West Virginia Wyoming Puerto Rico The Member's Mark Freeze Dried Fruit Variety Pack's being recalled are in 15 count boxes with a UPC number of 1 93968 50900 2, the FDA said. The agency added that no illnesses have been reported as of Thursday. The alert has a chart listing the recalled products with corresponding lot code numbers and use by dates for consumers to cross reference. The problem was discovered via "internal testing," the FDA says. A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) What People Are Saying The FDA on its website in part about the incubation period for Listeria infection: "There can be a substantial delay between the time of ingestion of contaminated food and the onset of serious symptoms. The average time from exposure to illness is approximately 30 days, but symptoms can appear as long as 90 days after exposure. It is important for consumers to know that the infection can occur as much as 90 days later, so that they can seek appropriate treatment if they have symptoms of Listeria infection." What Happens Next? Consumers are advised to contact Doehler Dry Ingredient Solutions, LLC's Customer Service via phone at (770) 387-0451 on weekdays from 8 a.m. to 5 p.m. ET with any additional questions, the FDA says. Health authorities continue to emphasize the importance of proper food storage and handling, particularly for ready-to-eat items. The FDA advises consumers to refrigerate perishable foods at and under 40°F, discard recalled products and properly sanitize surfaces that may have contacted suspected contaminated items to prevent the risk of cross-contamination.
Newsweek
an hour ago
- Newsweek
Medicare Update: Trump Admin Launching Pilot Program to Cover Ozempic
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Trump administration is preparing a five-year pilot program that would allow Medicare and Medicaid to cover some of the most in-demand weight-loss drugs, a move that could transform obesity treatment for millions of Americans. The plan, which includes medications such as Ozempic, Wegovy, Mounjaro and Zepbound, represents a reversal in federal policy and signals a broader willingness to use public insurance to address the nation's obesity epidemic. Why It Matters The drugs, known as GLP-1 receptor agonists, were initially developed to treat Type 2 diabetes but have become a cultural phenomenon for their ability to suppress appetite and help patients lose as much as 20 percent of their body weight in clinical trials. The pilot builds on a proposal introduced in the final months of the Biden administration but shelved earlier this year when officials under President Donald Trump announced Medicare and Medicaid would not cover weight-loss medications. What To Know According to documents obtained by The Washington Post, the program would allow state Medicaid programs and Medicare Part D plans to voluntarily cover GLP-1 drugs for weight management. The initiative is scheduled to begin in April 2026 for Medicaid and January 2027 for Medicare and will be administered through the Center for Medicare and Medicaid Innovation, which tests new payment models designed to reduce costs and improve care. Chiquita Brooks-LaSure, who led the Centers for Medicare and Medicaid Services under former President Joe Biden, told the Post the experiment would be a "game changer" if it expands access to obesity treatments. "Increased coverage of anti-obesity medications in Medicare and Medicaid was a priority during my tenure because scientists and clinicians increasingly believe obesity is a serious health condition that should be treated accordingly," she said. A pharmacy owner displays an Ozempic package in Pristina, Kosovo, on March 27. A pharmacy owner displays an Ozempic package in Pristina, Kosovo, on March 27. Photo by ARMEND NIMANI/AFP via Getty Images The program faces a major hurdle: price. GLP-1 drugs typically cost from $5,000 to $7,000 a year, raising questions about whether widespread coverage is sustainable. "The short-term cost is still huge," Dr. Cynthia Cox, vice president at KFF (formerly Kaiser Family Foundation), told Newsweek. "$1,000 a month per person is a massive outlay." A KFF analysis found that Ozempic's U.S. list price is $936 a month—more than five times the cost in Japan, where it sells for $169. Wegovy, which contains the same active ingredient, costs roughly $1,349 a month in the U.S., compared to $328 in Germany. At the moment, 13 state Medicaid programs cover GLP-1 drugs for obesity. Medicare limits coverage to patients with related conditions such as diabetes or heart disease. With about 70 million people enrolled in Medicaid and 65 million in Medicare, even partial expansion could affect a significant share of the population. Ethicists warn of the potential economic fallout. "These drugs help over 50 percent of people lose up to 25 percent of their body weight," said Dr. Robert Klitzman, a Columbia University bioethicist, in an interview with Newsweek. "But they cost around $12,000 a year. If two-thirds of Americans needed them, it would bankrupt the health care system." Despite the financial concerns, GLP-1 medications are generating enthusiasm among doctors for their ability to improve multiple health markers beyond weight loss. Clinical trials show they can reduce blood sugar, lower blood pressure and improve cardiovascular outcomes. "Ozempic and other GLP-1 drugs are changing how we approach obesity, both in the doctor's office and for society in general," Dr. Raj Dasgupta, chief medical adviser for Garage Gym Reviews, told Newsweek. "They're helping shift the conversation from 'this is a personal failure' to 'this is a medical condition that deserves real treatment.'" The Congressional Budget Office estimates that adding obesity coverage could cost Medicare $35 billion from 2026 to 2034. What People Are Saying A spokesperson for Novo Nordisk, which manufactures Ozempic and Wegovy, told The Washington Post: "We believe that comprehensive coverage through government and commercial insurance plans is critical to affordable health care and treatment options." Klitzman also said in the interview with Newsweek: "Insurance doesn't always cover it, especially for people who don't have diabetes or heart disease. Initially, the drugs were approved for diabetes-related obesity, but doctors have been prescribing them to people who are just overweight, without those conditions." What Happens Next With more than 100 million U.S. adults classified as obese and 22 million considered severely obese, according to the Centers for Disease Control and Prevention, the program's potential impact is vast. The proposal is not final and could undergo a formal public comment period before implementation.
Newsweek
6 hours ago
- Newsweek
Early Warning Signs For MS Discovered—Appear 15 Years Before Main Symptoms
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Warning signs for multiple sclerosis (MS) could emerge more than a decade before the first classical symptoms occur—offering hope for earlier detection and better patient outcomes. This is the finding of researchers from the University of British Columbia (UBC), who have analyzed the health records of more than 12,000 people in the Canadian province and challenged assumptions about when the disease really begins. They discovered those living with MS—a chronic condition affecting the brain and spinal cord—began using healthcare services at elevated rates 15 years before their first 'typical' MS symptoms appeared. While MS affects people differently, symptoms often include feeling extremely tired, problems with your eyes or vision, numbness or a tingling feeling in different parts of the body, feeling off balance, muscle cramps and concentration/memory problems. "MS can be difficult to recognize as many of the earliest signs—like fatigue, headache, pain and mental health concerns—can be quite general and easily mistaken for other conditions," said paper author and UBC neurology professor Helen Tremlett in a statement. "Our findings dramatically shift the timeline for when these early warning signs are thought to begin, potentially opening the door to opportunities for earlier detection and intervention." Female doctor is taking the blood pressure of a young adult female patient during a medical consultation. Female doctor is taking the blood pressure of a young adult female patient during a medical consultation. Antonio_Diaz/Getty Images The study offers a clear picture to date of how patients engage with a range of healthcare providers in the years leading up to a MS diagnosis as they search for answers to "ill-defined" medical challenges. Diagnosis for the condition typically requires imaging (MRI) signals and a specific clinical presentation. The study tracked physician visits in the 25 years leading up to the onset of a patient's MS symptoms, as determined by a neurologist through detailed medical history and clinical assessments. Most previous studies have only examined trends in the five to 10 years leading up to a patient's first "demyelinating event" (the loss or damage of the myelin sheath, a protective covering surrounding nerve fibers in the brain and spinal cord) such as vision problems. Bruce Bebo, Executive Vice President of Research for the National Multiple Sclerosis Society, told Newsweek, "This is an impressive study by a world-class research team offering important new insights into the earliest manifestations of MS. "The ability to identify people at high risk for MS could trigger enhanced monitoring and subsequent identification of people in the earliest stage of disease. Treatment of MS at this earliest stage would likely result in significantly improved outcomes." The researchers revealed that, compared to the general population, people with MS had a steady build-up of healthcare engagement over 15 years with different types of doctor visits increasing at particular points. Some 15 years before symptom onset, patient visits to general practice physicians increased, as did visits to any physician for symptoms like fatigue, pain, dizziness and mental health conditions. At 12 years before, visits to a psychiatrist increased. Three to five years before diagnosis, emergency medicine and radiology visits increased. And one year before, physician visits across multiple specialties peaked, including neurology, emergency medicine and radiology. "These patterns suggest that MS has a long and complex prodromal phase—where something is happening beneath the surface but hasn't yet declared itself as MS," said paper author and UBC postdoctoral fellow Marta Ruiz-Algueró in a statement. "We're only now starting to understand what these early warning signs are, with mental health-related issues appearing to be among the earliest indicators." The study follows previous work by Tremlett and her team to characterize the early stages of MS, known as the 'prodromal phase', where subtle signs or other symptoms occur before the onset of more typical symptoms. These periods are well established in other neurological disorders like Parkinson's disease, where mood changes, sleep disturbances and constipation often arise years before the more familiar motor symptoms like tremors and stiffness. While the researchers point out the vast majority of people who experience general symptoms like fatigue and headaches won't go on to develop MS, they say recognizing and characterising the MS prodrome could one day help accelerate diagnosis and improve outcomes for patients. "By identifying these earlier red flags, we may eventually be able to intervene sooner—whether that's through monitoring, support or preventive strategies," said Dr. Tremlett. "It opens new avenues for research into early biomarkers, lifestyle factors and other potential triggers that may be at play during this previously overlooked phase of the disease." Could we use these early signs to reduce risk of MS developing? Bebo said: "It is likely that the central nervous system is already affected at this early stage of the disease, making true prevention unlikely. However, initiating treatment with a disease-modifying therapy at this point could halt disease progression." However, he added, "Many consider the onset of MS begins when autoreactive immune cells gain access to the central nervous system and start causing damage. "If we can identify the very earliest changes in the immune system prior to entry into the central nervous system and prevent these cells from getting access to the brain and spinal cord, it might be possible to prevent MS." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about MS? Let us know via health@ Reference Ruiz-Algueró, M., Zhu, F., Chertcoff, A., Zhao, Y., Marrie, R. A., & Tremlett, H. (2025). Health Care Use Before Multiple Sclerosis Symptom Onset. JAMA Network Open, 8(8).
